Citigroup Inc. lowered its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Get Rating) by 32.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,686 shares of the biopharmaceutical company’s stock after selling 43,617 shares during the quarter. Citigroup Inc. owned about 0.15% of Xencor worth $2,361,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Xencor by 0.8% during the third quarter. BlackRock Inc. now owns 10,006,966 shares of the biopharmaceutical company’s stock worth $259,982,000 after buying an additional 83,291 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Xencor by 12.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,599,071 shares of the biopharmaceutical company’s stock valued at $180,617,000 after purchasing an additional 744,569 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Xencor by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,561,500 shares of the biopharmaceutical company’s stock valued at $170,467,000 after purchasing an additional 153,529 shares in the last quarter. Primecap Management Co. CA boosted its holdings in shares of Xencor by 18.7% in the 3rd quarter. Primecap Management Co. CA now owns 5,690,231 shares of the biopharmaceutical company’s stock valued at $147,832,000 after purchasing an additional 895,179 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Xencor by 9.4% in the 2nd quarter. State Street Corp now owns 3,247,981 shares of the biopharmaceutical company’s stock valued at $88,897,000 after purchasing an additional 279,080 shares in the last quarter. Institutional investors and hedge funds own 98.99% of the company’s stock.
Insider Transactions at Xencor
In other news, VP Celia Eckert sold 2,462 shares of Xencor stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $31.42, for a total value of $77,356.04. Following the completion of the transaction, the vice president now directly owns 37,687 shares of the company’s stock, valued at approximately $1,184,125.54. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CFO John J. Kuch sold 919 shares of Xencor stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $31.54, for a total value of $28,985.26. Following the completion of the transaction, the chief financial officer now directly owns 129,715 shares of the company’s stock, valued at approximately $4,091,211.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Celia Eckert sold 2,462 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $31.42, for a total value of $77,356.04. Following the completion of the sale, the vice president now directly owns 37,687 shares of the company’s stock, valued at $1,184,125.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,740 shares of company stock valued at $739,628. Corporate insiders own 4.97% of the company’s stock.
Wall Street Analysts Forecast Growth
Xencor Stock Up 3.4 %
Shares of NASDAQ:XNCR opened at $28.72 on Wednesday. Xencor, Inc. has a 12-month low of $19.35 and a 12-month high of $38.20. The business has a fifty day simple moving average of $27.81 and a 200 day simple moving average of $29.28.
Xencor (NASDAQ:XNCR – Get Rating) last announced its earnings results on Monday, May 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.27). The company had revenue of $18.90 million for the quarter, compared to the consensus estimate of $26.89 million. Xencor had a negative return on equity of 19.41% and a negative net margin of 142.32%. The firm’s revenue for the quarter was down 77.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.39 earnings per share. On average, analysts forecast that Xencor, Inc. will post -2.99 EPS for the current fiscal year.
About Xencor
Xencor, Inc is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More
- Get a free copy of the StockNews.com research report on Xencor (XNCR)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR – Get Rating).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
